1 REDUCTION OF AMPHOTERICIN B INDUCED RENAL TUBULAR APOPTOSIS BY N-ACETYLCYSTEINE Running Title : N-acetylcystein and amphotericin B nephrotoxicity

[1]  G. Jensen,et al.  Comparative Efficacies, Toxicities, and Tissue Concentrations of Amphotericin B Lipid Formulations in a Murine Pulmonary Aspergillosis Model , 2006, Antimicrobial Agents and Chemotherapy.

[2]  N. Marcussen,et al.  N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  P. Persson,et al.  Contrast medium-induced nephropathy: the pathophysiology. , 2006, Kidney international. Supplement.

[4]  P. Parfrey,et al.  Preventing Nephropathy Induced by Contrast Medium , 2006 .

[5]  S. Efrati,et al.  N-Acetylcysteine Ameliorates Amphotericin-Induced Nephropathy in Rats , 2004, Nephron Physiology.

[6]  A. Colombo,et al.  Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. , 2004, European heart journal.

[7]  S. Piscitelli,et al.  Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits , 2003, Antimicrobial Agents and Chemotherapy.

[8]  M. Tepel,et al.  Acetylcysteine for the prevention of radiocontrast -induced nephropathy. , 2003, Minerva cardioangiologica.

[9]  R. Herbrecht,et al.  The lipid formulations of amphotericin B , 2003, Expert opinion on pharmacotherapy.

[10]  R. Walter,et al.  Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  B. Villari,et al.  Acetylcysteine and contrast agent-associated nephrotoxicity. , 2002, Journal of the American College of Cardiology.

[12]  S. Pestotnik,et al.  The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. , 2001, The American journal of medicine.

[13]  C. Girmenia,et al.  Nephrotoxicity of amphotericin B desoxycholate. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Colleen Carrigan Harrell,et al.  Comparison of nephrotoxicity of amphotericin B products. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  U. Eriksson,et al.  Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial , 2001, BMJ : British Medical Journal.

[16]  D. Bates,et al.  Mortality and costs of acute renal failure associated with amphotericin B therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  L. Parton,et al.  Apoptosis Contributes to Amphotericin B- Induced Nephrotoxicity , 2001, Antimicrobial Agents and Chemotherapy.

[18]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.

[19]  V. Fanos,et al.  Amphotericin B-Induced Nephrotoxicity: A Review , 2000, Journal of chemotherapy.

[20]  E. Anaissie,et al.  Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  L. Bouzas,et al.  Comparison of the Toxicity of Amphotericin B in 5% Dextrose with That of Amphotericin B in Fat Emulsion in a Randomized Trial with Cancer Patients , 1999, Antimicrobial Agents and Chemotherapy.

[22]  B. Guglielmo,et al.  Lipid formulations of amphotericin B: clinical efficacy and toxicities. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Ganser,et al.  Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study , 1998, BMJ.

[24]  P. Halpern,et al.  Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. , 1996, Critical care medicine.

[25]  O. Casasnovas,et al.  A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. , 1994, The Journal of antimicrobial chemotherapy.

[26]  K. Winnefeld,et al.  Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats , 1993, Journal of applied toxicology : JAT.

[27]  P. Moreau,et al.  Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. , 1992, The Journal of antimicrobial chemotherapy.

[28]  W. Bullock,et al.  GENITOURINARY SYSTEM: Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys , 1977 .

[29]  H. Abrams,et al.  Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. , 1970, Investigative radiology.

[30]  S. Fishbane.  N-acetylcysteine in the prevention of contrast-induced nephropathy. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[31]  M. Schultz,et al.  UvA-DARE ( Digital Academic Repository ) Bench-to-bedside review : preventive measures for contrast-induced nephropathy in critically ill patients , 2005 .

[32]  R. Solomon,et al.  Contrast-medium-induced acute renal failure. , 1998, Kidney international.

[33]  P. Kurnik,et al.  Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. , 1994, Kidney international.

[34]  G. Bakris,et al.  Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. , 1990, The American journal of physiology.